Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes

Jan 21, 2022Obesity surgery

Liraglutide’s safety and effectiveness for poor weight loss and weight regain after initial and follow-up weight loss surgery, including body and heart health measures

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Liraglutide reduced weight by an average of 5.97% in primary bariatric surgery patients after 12 months.

The study included 145 adults, with 82% having undergone primary bariatric surgery.
Liraglutide was administered approximately 54 months after surgery, primarily for weight regain (74.3%).
Both primary and revisional patients experienced significant reductions in weight and BMI after treatment.
52.3% of primary patients and 60% of revisional patients lost at least 5% of their total weight after 6 months.
Liraglutide did not enhance cardiometabolic outcomes in primary patients, with only systolic blood pressure decreasing in revisional patients.
The treatment was generally well tolerated, with nausea being the most frequently reported side effect.

AI simplified

BACKGROUND: No study appraised the effectiveness and safety of liraglutide in managing inadequate weight loss or weight regain (IWL/ WR) after primary versus revisional bariatric surgery (BS).

METHODS: Retrospective study of all eligible adults who completed liraglutide 3 mg therapy for IWL/WR after primary or revisional BS at our institution between May 2016 and June 2019 (N = 145; 119 primary, 82%; 26 revisional, 18%). Changes in anthropometric and cardiometabolic parameters were assessed before the start of liraglutide and at 6 and 12 months after treatment.

RESULTS: The mean age was 43.32 ± 10.49 years, and 83% were females. Patients received liraglutide at a mean of 54.10 ± 31.75 months after their BS, for WR (74.3%) or IWL (25.6%). Liraglutide significantly reduced weight and BMI among primary and revisional patients (P < 0.0001 for all) and was equally effective in these reductions for both groups. Primary patients achieved total weight loss percentage (TWL%) of 5.97% and 6.93% at 6 and 12 months. Additionally, 52.3% and 60% of the patients lost ≥ 5% of their total weight (TW) at 6 and 12 months after primary BS. Revisional patients achieved TWL% of 6.41% and 4.99% at 6 and 12 months, and 60% and 48% of patients lost ≥ 5% TW at the two time points. Liraglutide did not improve cardiometabolic outcome for primary patients; for revisional patients, only the systolic blood pressure decreased after treatment. Liraglutide was well tolerated, and the most common side effect was nausea.

CONCLUSIONS: Liraglutide is useful as an adjunct weight loss medication for patients achieving unsatisfactory outcomes with BS.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief